Drug intelligence / Profile preview

UNI500

Development stage: Unknown
Lead developer: UNION therapeutics
Modality: Small Molecules
Administration: Oral, Topical

Overview

UNI500 is a **small-molecule phosphodiesterase type 4 inhibitor series** acquired by UNION Therapeutics from LEO Pharma and renamed from the original LEO PDE4 program. The lead candidate in the series is **orismilast**, which has been developed in **oral** and **topical** formulations for inflammatory dermatologic diseases. Based on the provided context, the program advanced to **Phase 2** in **psoriasis** for oral orismilast and in **atopic dermatitis** for topical orismilast, with randomized placebo-controlled studies reported to show superiority over placebo.

Other names: orismilast

Targets

PDE4 (Phosphodiesterase 4A1)

Beyond the preview

Go deeper on UNI500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UNI500.

Explore the full profile